| Literature DB >> 27134116 |
Claudia Vergelli1, Igor A Schepetkin2, Giovanna Ciciani1, Agostino Cilibrizzi3, Letizia Crocetti1, Maria Paola Giovannoni4, Gabriella Guerrini1, Antonella Iacovone1, Liliya N Kirpotina2, Andrei I Khlebnikov5, Richard D Ye6, Mark T Quinn2.
Abstract
N-Formyl peptide receptors (FPRs: FPR1, FPR2, and FPR3) are G protein-coupled receptors that play key roles in modulating immune cells. FPRs represent potentially important therapeutic targets for the development of drugs that could enhance endogenous anti-inflammation systems associated with various pathologies, thereby reducing the progression of inflammatory conditions. Previously, we identified 2-arylacetamide pyridazin-3(2H)-ones as FPR1- or FPR2-selective agonists, as well as a large number of FPR1/FPR2-dual agonists and several mixed-agonists for the three FPR isoforms. Here, we report a new series of 2-arylacetamido-4-aniline pyridazin-3(2H)-ones substituted in position 5 as a further development of these FPR agonists. Chemical manipulation presented in this work resulted in mixed FPR agonists 8a, 13a and 27b, which had EC50 values in nanomolar range. In particular, compound 8a showed a preference for FPR1 (EC50=45nM), while 13a and 27b showed a moderate preference for FPR2 (EC50=35 and 61nM, respectively). Thus, these compounds may represent valuable tools for studying FPR activation and signaling.Entities:
Keywords: Agonist; Ca(2+) mobilization; Formyl peptide receptor (FPR); Neutrophil; Pyridazin-3(2H)-one
Year: 2016 PMID: 27134116 PMCID: PMC5055850 DOI: 10.1016/j.bmc.2016.04.019
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641